At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 50 enrolled
Drug / intervention
Rotigotine transdermal patchdrug
Likely dose
Rotigotine transdermal patch 4.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-site, Open-label, Randomized, Cross-over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm2) Comparing Two Different Formulations
In Brief
A Phase 1 clinical trial evaluating Rotigotine transdermal patch for Healthy Volunteers. Completed, enrolled 50 participants across 1 site.
Detailed Summary
The major aim of this study is to investigate and compare the drug amount delivered to the body after sequential application of two Rotigotine patches of two different formulations
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedFeb 2010
Primary CompletionFeb 2010
Study CompletionMar 2010
TodayJul 2026
First PostedFeb 1, 2010
Enrollment StartJan 1, 2010
Primary CompletionFeb 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.4 years ago
Interventions
Rotigotine transdermal patchdrug
Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours